Favipiravir is an antiviral medicine officially approved in India as a treatment for COVID 19 in its mild form. Favipiravir has been used in Japan since 2014 in the treatment of influenza.
Favipiravir works by bocking RNA polymerase which helps the virus replicate. In this way Favipiravir lowers the viral load of the coronavirus.
As with most medicines, Favipiravir can have side effects. These may include: increased uric acid, lower white blood cell count, elevated liver enzymes and diarrhea. Discontinue if side effects are bothersome or if you have an allergic reactions.
Do not take if you have a history of gout. Favipiravir is not recommended by those pregnant, suspected of being pregnant or breastfeeding.
The standard dosing schedule in India for mild COVID is 1800mg (9 tablets) twice daily on day 1, then 800mg (4 tablets) twice daily on subsequent days up to a maximum of 14 days of treatment/